🔴 Humacyte Trades Down 10.15% in Pre-Market Following Q2 Revenue Miss and Higher-Than-Expected Loss

Humacyte is trading at $0.64 (-10.15%) in pre-market as investors react to its August 12, 2026, second-quarter results.

• The company reported Q2 product revenue of $0.4 million, falling short of the consensus expectation of $1.12 million.
• Humacyte announced a net loss of $36.8 million for Q2 2026, equating to approximately $0.16 per share, exceeding the consensus expected loss of $0.10 per share.
• This financial performance appears to overshadow positive clinical updates, including breakthrough Phase 3 results for its dialysis access study.